Establishment of a bioluminescent imaging-based in vivo leukemia model by intra-bone marrow injection.

@article{Lee2012EstablishmentOA,
  title={Establishment of a bioluminescent imaging-based in vivo leukemia model by intra-bone marrow injection.},
  author={Myoung-Woo Lee and Hye Jin Kim and Keon Hee Yoo and Dae Seong Kim and Jin Mo Yang and Hye Ryung Kim and Yoo Hun Noh and Hyun-jung Baek and Heechung Kwon and Meong Hi Son and Soo Hyun Lee and Hee won Cheuh and Hye Lim Jung and Ki Woong Sung and Hong Hoe Koo},
  journal={International journal of oncology},
  year={2012},
  volume={41 6},
  pages={
          2047-56
        }
}
In vivo leukemia mouse models are usually generated by intraperitoneal (IP) or intravenous (IV) injection of leukemia cells. However, the pattern of leukemia development observed can be inconsistent. This study investigated injection directly into bone marrow [intra-bone marrow transplantation (IBMT)], the natural microenvironment of leukemia. A bioluminescent imaging-based leukemia animal model has been established by direct injection… 
View on PubMed
spandidos-publications.com
6 Citations
Highly Influential Citations
1
Background Citations
1
Methods Citations
1

Figures from this paper

6 Citations

Citation Type

Citation Type

Capacity of the medullary cavity of tibia and femur for intra-bone marrow transplantation in mice
TLDR
For optimal cell transplantation via IBMT in mice, it is suggested to inject a high concentrated cell suspension with a maximum injection volume of 3 μL, rather than the commonly used 10 and 40 μL.
Assessment and refinement of intra-bone marrow transplantation in mice
TLDR
The results revealed that IBMT definitely induces severe post-operative distress, and although IBMT in the tibia is technically easier, the degree of impairment and the distress observed were consistently higher than for transplantation in the femur.
Impact of the Injection Site on Growth Characteristics, Phenotype and Sensitivity towards Cytarabine of Twenty Acute Leukaemia Patient-Derived Xenograft Models
TLDR
All three application routes turned out to be feasible for the propagation of PDX and the distinct differences between the settings highlight the need for well characterized platforms to ensure the meaningful interpretation of data generated using those powerful tools.
Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management
TLDR
Experimental P-bi-TAT therapy in vivo appears extraordinarily effective against the two forms of human AML models in mice, and represents a promising targeted therapeutic agent for AML patients.
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
TLDR
Results indicate that gilteritinib may be an important next-generationFLT3 inhibitor for use in the treatment of FLT3 mutation-positive AML.
Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration
TLDR
The specific alteration of renal transporters and glomerular filtration in kidneys provide a rational explanation for changes in pharmacokinetics for ALL.

References

SHOWING 1-10 OF 41 REFERENCES
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis
TLDR
Its application to traditional oncology animal models offers quantitative and sensitive analysis of tumor growth and metastasis and improves upon current standard animal models that are based on single end point data.
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.
TLDR
This study demonstrates that the use of bioluminescent primary ALL allows the detection and quantitation of treatment effects at earlier, previously unquantifiable disease burdens and thus provides the means to standardize and expedite the evaluation of anti-ALL activity in preclinical xenograft studies.
Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice.
In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals
TLDR
Although in vivo bioluminescence imaging would allow non-invasive monitoring of leukaemia model animals, environmental factors and therapeutic interventions may cause some discrepancies between tumour burden and biolUMinescence intensity.
Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice
TLDR
The findings suggest that xenotransplantation into immunodeficient mice provides a useful model to study the leukemia niche, and reveal that the epiphysis was the most active site for leukemia cell proliferation.
Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model.
Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy.
Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model
TLDR
A protocol to expand human GDTc in vitro, yielding highly cytotoxic Vgamma9/Vdelta2 CD27/CD45RA double negative effector memory cells, and a fluorescent and bioluminescent Ph+ cell line, EM-2eGFPluc, which is established a novel xenogeneic leukemia model.
In Vivo Bioluminescence Imaging of Murine Xenograft Cancer Models with a Red-shifted Thermostable Luciferase
TLDR
Two different bioluminescent mouse cancer models demonstrate the utility of a new red-shifted thermostable luciferase, Ppy RE-TS, that improved the in vivo imaging performance when compared with wild-type P. PyralisLuciferase.
A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.
TLDR
Evaluating the effects of NF-kappaB disruption by a proteasomal inhibitor (PS-341) and osteoclastic inhibition by zoledronic acid (Zol) on the development of ATLL and HHM using a novel bioluminescent mouse model indicates that both PS-341 and Zol are effective treatments for ATLL.
...
1
2
3
4
5
...